> GlaxoSmithKline has purchased dermatology company Stiefel Labs in a $3.6B 'targeted' buyout. Report
> The Wall Street Journal examines why Provenge wasn't made available sooner to the 30,000 American men who die each year from prostate cancer. Report
> London-based global CRO Chiltern International today announced the acquisition of Vigiun, a full service CRO located in Sao Paulo, Brazil. Release
> Abraxis BioScience says that its board of directors authorized a program to repurchase up to $100 million of the company's common stock. Release
> Peregrine Pharmaceuticals has reported positive preliminary data from a Phase II trial of bavituximab for lung cancer. Release
> China's distrust of its own domestic drug supply have made the country ripe for Big Pharma's growth there. Report
> At least one big-time pharma attorney isn't amused by the FDA's recent spate of Internet-search-ad warning letters. Though drug-safety concerns top the list of new-FDA worries for Morgan Lewis FDA/healthcare practice chief Kathleen Sanzo, she's also more than a bit nonplussed by the agency's stance on the search-ad issue. Report
> Apparently, Carl Icahn's (photo) proxy battle for Amylin is an attempt to engineer a sale to Lilly. Report
> Vermont lawmakers are trying to sharpen the teeth of the state's doctor-disclosure law, which requires pharma companies to detail their payments to physicians. Report
And Finally... British scientists say they have developed a stem procedure that will reverse the most common cause of blindness, age-related macular degeneration. Report